Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28392114 | 0.81 | KMT2A (0.43) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL5030964 | 0.78 | KMT2A (0.49) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL2580034 | 0.76 | ALDH1A1 (0.47) | KMT2A | |
| SCHEMBL16144632 | 0.75 | KMT2A (0.65) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31277783 | 0.74 | KMT2A (0.71) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL610115 | 0.74 | KMT2A (0.71) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL831613 | 0.74 | KMT2A (0.51) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29352060 | 0.74 | KMT2A (0.67) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30125177 | 0.74 | KMT2A (0.67) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29443815 | 0.74 | KMT2A (0.67) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117001-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | ERISYON INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4696680-A1 | DUAL-FUNCTIONAL TETRAZINE COMPOUNDS FOR VERSATILE RADIOLABELING WITH RADIOMETALS AND RADIOHALOGENS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | disclosed |
| EP-4696686-A1 | FAPI THERANOSTIC COMPOUNDS ASSEMBLED WITH TETRAZINE LIGATION | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | disclosed |
| EP-4639171-A2 | (POLY)LABEL SIGNAL ENHANCER | Roche Diagnostics GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250237656-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250186571-A1 | EPITOPE-TARGETED PEPTIDE IMMUNOSTIMULANTS | INSTITUTE FOR SYSTEMS BIOLOGY | 2025-06-12 | — | — | US | disclosed |
| US-12209142-B2 | SARS-CoV-2 epitope-targeted peptide immunostimulants | INSTITUTE FOR SYSTEMS BIOLOGY (US) | 2025-01-28 | — | — | US | disclosed |
| US-12201679-B2 | Epitope-targeted peptide immunostimulants | INSTITUTE FOR SYSTEMS BIOLOGY (US) | 2025-01-21 | — | — | US | disclosed |
| CN-118696234-A | Method for detecting target analytes in a sample | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024173611-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING CANDIDATE TARGETING BIOMOLECULES | AIZEN THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1802612-A1 | NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007053358-A2 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006135786-A2 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1694693-A2 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | Praecis Pharmaceuticals Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2006044412-A1 | NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050158765-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2005058479-A2 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201679-B2 | Epitope-targeted peptide immunostimulants | MICA, ICOS, CD47 | KMT2A 2324/4885FABP5 427/4885FABP7 888/4885 |
| US-20050158765-A1 | Methods for synthesis of encoded libraries | RNGTT, DTYMK, DUT | KMT2A 1848/4885FABP5 2281/4885FABP7 2825/4885 |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | BDKRB1, BDKRB2, EDNRB | KMT2A 3920/4885FABP5 2652/4885FABP7 1341/4885 |
| US-12209142-B2 | SARS-CoV-2 epitope-targeted peptide immunostimulants | ACE2, CD14, ICOSLG | KMT2A 2622/4885FABP5 223/4885FABP7 782/4885 |
| US-20250186571-A1 | EPITOPE-TARGETED PEPTIDE IMMUNOSTIMULANTS | MICA, ICOS, CD47 | KMT2A 2324/4885FABP5 427/4885FABP7 888/4885 |
| US-20260117001-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | QPCTL, QRFPR, CD47 | KMT2A 968/4885FABP5 1710/4885FABP7 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.